Key Metrics of Panacea Biotec
About Panacea Biotec
Sectors
Company details
- Website
- panacea-biotec.com
- Founded
- 1984
- Registered office
- Ambala-chandigarh Highway Lalru, Punjab, In-pb, 140501
- Listed
- NSE: PANACEABIO · ₹306.75
Operational Areas of Panacea Biotec
Company summary
Entity details
Compliance
Industry classification
Financials, ratios and risk analysis
Revenue, EBITDA, net profit, net worth, debt and assets for every filing year, 15+ ratios, the financial health score, shareholding, charges and peer comparison are part of the premium plan.
Sign in to continue See plans & pricingFiling compliance
Due dates follow the Companies Act: AGM within six months of the year end, AOC-4 within 30 days and MGT-7 within 60 days of the AGM. A filing made but not yet uploaded here shows as pending.
Vendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Credit ratings
Rating history
Rating actions
| Date | Agency | Action | Long term | Short term | Outlook | Rated amount | Rationale |
|---|---|---|---|---|---|---|---|
| 30 Dec 2019 | CARE | Other | — | — | — | — | View |
| 08 Feb 2019 | CARE | Reaffirmed | D | — | — | ₹2,043 Cr | View |
| 07 Dec 2017 | CARE | Revised (from B+) | D | — | Stable | ₹2,043 Cr | View |
| 26 Sep 2017 | CARE | Revised (from D) | B+ | A4 | Stable | ₹2,043 Cr | View |
| 20 Sep 2017 | CARE | Revised (from B+) | D | — | — | ₹2,043 Cr | View |
| 12 Aug 2016 | CARE | Reaffirmed (from B-) | B+ | A4 | — | ₹2,043 Cr | View |
| 31 Mar 2016 | CARE | Assigned (from D) | B- | A4 | — | ₹2,530 Cr | View |
| 23 Apr 2015 | CARE | Reaffirmed | D | — | — | ₹1,114 Cr | View |
| 11 Feb 2014 | CARE | Assigned | D | — | — | ₹1,114 Cr | View |
Credit strengths (CARE, Feb 2019)
+ Outlook Fund-based-Long Term -
Sep-2023 959.55 CARE D Non-fund-based-Short - - - 61.97 CARE D Term 2 CARE Ratings Limited Press Release Annexure-2: Rating History of last three years Sr.
Credit challenges
− Delays in servicing of debt obligations
The company has delayed in the servicing of the debt obligations on the instalments of its loan obligations on account of the weak liquidity position of the company. Weak financial risk profile The Total income from operations increased to Rs 589.49 crore in FY18 from Rs 546.76 crore in FY17 due to increased sale of vaccine EasySix in the domestic market, sale of oral polio vaccine to Government of India and growth in the
− Weak financial risk profile
The Total income from operations increased to Rs 589.49 crore in FY18 from Rs 546.76 crore in FY17 due to increased sale of vaccine EasySix in the domestic market, sale of oral polio vaccine to Government of India and growth in the pharmaceutical formulations business. PBL has incurred loss of Rs 73.29 crore in FY18 as against a loss of Rs 73.43 crore in FY17. Overall gearing moderated to 2.62x as on 31st Mar 2018 as compared to 2.35x as on 31st Mar 2017.
− Key Rating Strengths
Experienced promoters and management team and long track record of operations The Company has been in the pharmaceutical business since 1984 and has a long track record of operations of more than 30 years. The company is promoted by the Jain family headed by Mr Soshil Kumar Jain who has an experience of more than 50 years in the pharmaceutical industry. He is assisted by Dr Rajesh Jain and Mr Sandeep Jain in looking after the
Borrowings & rated debt
Rated limits over time
Facility mix
Rated facilities
| Facility | Type | Previous | Current | Change | Rating | Action | Agency |
|---|---|---|---|---|---|---|---|
| Facilities Action Long term Bank Facilities | Working capital & bank lines | — | ₹960 Cr | — | D | Reaffirmed | CARE |
| Short term Bank Facilities | Working capital & bank lines | — | ₹62.0 Cr | — | D | Reaffirmed | CARE |
| Total (Rupees One thousand twenty one crore fifty two lakh only) | Other | — | ₹1,022 Cr | — | — | Other | CARE |
CARE ratings on record (checked 23 Oct 2026)
| Instrument | Amount | Rating |
|---|---|---|
| Commercial Paper | — | Withdrawn |
| Long Term | — | Withdrawn |
| Short Term | — | Withdrawn |
Credit assessment · Manufacturing
Rating Methodology – Manufacturing Companies (Mar 2025) · Standalone accounts · FY 2025-26
Ratios, pillar scores and the indicative rating are part of Premium.
Rating status
| Default | Last default 08 Feb 2019 |
| Issuer cooperation | Cooperating |
| Credit enhancement | None – standalone rating |
| Next action stable or better (model) | 35% |
| Information on file | 67% · missing: Capex / investment plans, Auditor details, Recent rating review (last 15 months) |
Indicative assessment from public data using the published methodology factors; not a credit rating.
Borrowing & funding lifecycle
- Credit outlook model: 41% chance the next rating action is stable or better
Rated limits by facility
Timeline
Lender names, bank charges and audited borrowings are part of Premium.
Built from MCA charges, ICRA/CARE rating reports and audited accounts. The borrowing view is an estimate, not a lender's credit decision.
Registered office and contact
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of Panacea Biotec
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
 Dr. Reddy's Laboratories |
Part of Dr. Reddy's Laboratories. | drreddys.com | 1984 | India |
 Aurobindo Pharma |
Part of Aurobindo Pharma. | aurobindo.com | 1986 | Hyderabad, India |
 Cipla |
Part of Cipla. | cipla.com | 1935 | Mumbai, India |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | lupin.com | 1968 | India | |
 Glenmark Pharmaceuticals |
Part of Glenmark Pharmaceuticals. | glenmarkpharma.com | 1977 | Mumbai, India |
| Part of Biocon. | biocon.com | 1978 | Bangalore, India | |
 ALKEM LABORATORIES LIMITED |
Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | alkemlabs.com | 1973 | Mumbai, Maharashtra, India |
 Torrent Pharmaceuticals |
Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | torrentpharma.com | 1959 | Ahmedabad, India |
 Thomas Cook India |
Part of Thomas Cook Group. | thomascook.in | 1978 | Mumbai, India |
 Divi's Laboratories |
Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | divislabs.com | 1990 | Hyderabad, India |
Similar companies
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
pharmaceutical industry
Filings
No filings on record yet.